Cabazitaxel
- Generic Name
- Cabazitaxel
- Brand Names
- Jevtana, Cabazitaxel Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C45H57NO14
- CAS Number
- 183133-96-2
- Unique Ingredient Identifier
- 51F690397J
- Background
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like paclitaxel and docetaxel.
Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
- Indication
用于治疗转移性去势抵抗性前列腺癌患者。
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer
- Conditions
- Prostate Cancer Metastatic
- Interventions
- First Posted Date
- 2014-02-28
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 10
- Registration Number
- NCT02074137
- Locations
- 🇮🇳
Investigational Site Number 356003, New Delhi, India
🇮🇳Investigational Site Number 356005, Kollkata, India
🇮🇳Investigational Site Number 356002, Trivandrum, India
Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 195
- Registration Number
- NCT02044354
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Registration Number
- NCT02035124
- Locations
- 🇺🇸
Florida Cancer Specialists-South, Ft. Myers, Florida, United States
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
🇺🇸Tennessee Oncology PLLC, Nashville, Tennessee, United States
The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Nova Scotia Cancer Centre
- Registration Number
- NCT01981668
Efficacy Study Evaluating Chemotherapy in Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: Androgen deprivation therapy
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Örebro University, Sweden
- Target Recruit Count
- 400
- Registration Number
- NCT01978873
- Locations
- 🇸🇪
University Hospital of Örebro, Örebro, Sweden
Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Target Recruit Count
- 65
- Registration Number
- NCT01956149
- Locations
- 🇩🇪
Krankenhaus Dresden Friedrichstadt, Dresden, Germany
🇩🇪Krankenhaus Nordwest, Frankfurt am Main, Germany
🇩🇪Universitätsklinikum Jena, Jena, Germany
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
- Conditions
- Adenocarcinoma of ProstateProgression of Prostate Cancer
- Interventions
- First Posted Date
- 2013-09-27
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 761
- Registration Number
- NCT01952223
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Neoadjuvant Chemotherapy With Cabazitaxel
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2016-09-13
- Lead Sponsor
- RWTH Aachen University
- Target Recruit Count
- 11
- Registration Number
- NCT01941550
- Locations
- 🇩🇪
Uniklinik RWTH Aachen, Aachen, Nordrhein-Westfalen, Germany
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
- Conditions
- Metastatic Breast Cancer With Intracranial Metastases
- Interventions
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 11
- Registration Number
- NCT01934894
- Locations
- 🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States
🇺🇸Oncology Hematology Care Inc., Cincinnati, Ohio, United States
🇺🇸Florida Cancer Specialists-North, Saint Petersburg, Florida, United States
Ph II Cabazitaxel DD Liposarcoma
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2021-09-14
- Target Recruit Count
- 42
- Registration Number
- NCT01913652
- Locations
- 🇧🇪
Universitair Ziekenhuis Antwerpen (117), Antwerpen, Belgium
🇮🇹Istituto Oncologico Veneto IRCCS - Ospedale Busonera (3908), Padova, Italy
🇫🇷Centre Leon Berard (227), Lyon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.